



October 2021

Safe Harbor Statement

Statements contained in this presentation that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations of Nanomix and its management with respect to the further development of COVID-19 tests. Such statements, which are only expectations, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events or performance may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to the following, any of which could be exacerbated even further by the continuing COVID-19 outbreak in the United States and globally: the ability of Nanomix to timely obtain regulatory approvals for its proposed Nanomix eLab COVID-19 diagnostic tests; Nanomix's dependence upon, and limited experience with, COVID-19 diagnostic tests; the highly competitive and rapidly developing market for testing solutions for COVID-19, which includes a number of competing companies with strong relationships with current and potential customers, including governmental authorities, and with significantly greater financial and other resources that are available to Nanomix. Nanomix undertakes no obligation to publicly update forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Nanomix's expectations with regard to the forward-looking statements or the occurrence of unanticipated events.

Nanomix eLab® is a registered trademark.

Nanomix Delivers On the Promise of Point of Care Testing

- Leader in decentralized testing – large, fast-growing market
 - Need for decentralized testing is reinforced by COVID-19 experience
- Most Advanced Mobile Diagnostic System
 - One instrument for many different tests
 - Lab quality results in an easy-to-use system
 - Robust and connected for use in ambulance, ER, assisted living, Dr. office, events, airports...
- Deep Technical Expertise and IP
 - All technology developed and wholly owned by Nanomix
 - 29 issued and pending patents
- Market Ready Critical Infection Panel – a game changer for clinical diagnosis
 - The **ONLY** portable, rapid PCT assay
 - Drives unique rapid testing solutions for sepsis / pneumonia

Publicly Listed via Reverse Merger

- Reverse merger with Boston Therapeutics (OTCQB:BTHE) completed June 2021
 - Name and Ticker Symbol change in process
 - 54.6 million shares (fully diluted) post reverse split in process
- Convertible Equity financing completed post merger
 - \$8.4M Notes placement; aggregate purchase price of \$7.9M
 - Total new funding of \$5.8M
 - Initial conversion price of \$0.0119 per share (\$2.0587 post reverse split)

Point-of-Care Testing (POCT) – A \$20B Market Ripe for Disruption




**Nanomix: the first system to deliver
laboratory quality results on a portable platform**

Decentralized Diagnostic Testing Venues

Testing at POC improves the patient experience and will lower costs


The Institute of Medicine (IOM) estimates that **\$750 billion**—30% of the U.S. annual health care budget—is **wasted** on unnecessary services, inefficient delivery, excessive administrative costs and prevention failures

...studies have reported that up to **34%** of Medicare patients transported by EMS to an ED **could have been safely treated in an alternative setting**¹




The Nanomix system is **based on proprietary, innovative technology** providing significant advantages in accuracy, portability and cost

Nano-Electric Sensors with Electro-Chemical Detection



- Advantages over traditional optical techniques
- Multiplex and multiple assay techniques
- Inexpensive, sensitive sensors

Precision Sample Preparation in a **Microfluidic Cartridge**



- Precision movement of fluids via programmatic control of assay protocols
- Enables reproducibility on a portable instrument

Easy to use **Portable Analyzer**



- Designed for use in or outside of traditional laboratory environments
- Menu driven screens for intuitive use
- Minimal training for non-professionals

Technology developed and wholly owned by Nanomix including 29 issued and pending patents

Nanomix eLab

A Complete Mobile Immunoassay Diagnostic System



ACCURATE

Proprietary sensor technology brings immunoassay sensitivity and specificity to the POC

FAST

Microfluidics technology delivers reproducibility and a quick 10 – 15 minutes sample-to-answer

MOBILE

Rugged design and menu driven software enables use in mobile settings with limited training

CONNECTED

Store data, send HL7 or simple text data via Bluetooth, or display results in QR format

Intuitive Menu-Driven Testing



① Scan test cartridge



② Load patient sample




③ Insert test cartridge and push 'go'



④ Results Bluetooth via QR code

Focus on high-value markets




Rapid Tests for Improved Patient Outcomes



S1 assay panel is first element of Nanomix strategy: target assays where **high accuracy and immediacy** are of great value in **patient care**.

Critical Infections

A Global Health Challenge



Critical Infection Assay Panel (S1)

Unique Mobile POC Solution

Differentiated

- **Only** POC multiplexed panel for PCT, CRP, & LAC
- Results in 11 minutes
- Lab quality results

Credible


- **Proven** in Multi-center clinical trials
- Consistent with current clinical information
- CE Marked

Customer Ready


- **Critical** results in 11 minutes transforms standards of care
- Evaluation trials underway in Europe

S1 Assay Panel Addresses Major Needs


Disease	Clinical Impact
Global health challenges <ul style="list-style-type: none">• Pneumonia• Sepsis• COPD exacerbation• Critical infections<ul style="list-style-type: none">-Bacteremia-Blood stream-Upper respiratory-Urinary tract-Postoperative	Timely host response diagnostics improve patient outcomes <ul style="list-style-type: none">Reduce 30-day mortalityReduce antibiotic exposureReduce healthcare acquired complicationsImprove transition of care decisions




S1 Assay Panel – Large Addressable Market



Broadening the number of tests expands TAM...



Nanomix go to market via **established distribution partners**



Focused and Efficient Staffing

Nanomix staff can support hundreds of distribution sales representatives through technical sales support and training

Customer Acquisition

Leverage existing relationships between distributor and end-user customers. Access large buyers through existing buying contracts

Customer Support

Technical support, implementation, and product delivery execution through a proven network

Migrate to a direct sales model in major markets

Business model

Revenue and margin driven by consumable cartridge sales



ELAB ANALYZER

- Analyzer runs multiple cartridge types

RETAIL
PRICE

\$8,000

MARGIN
TARGET

~25%



CARTRIDGES

- Primary Source of Revenue
- À la carte pricing based on specific tests
- Single use

RETAIL
PRICE

\$10-50+

MARGIN
TARGET

50-90%

Monthly rental and subscription programs available

Innovative Diagnostic Platforms Create Value

INNOVATOR		ACQUIRER
ALERE	➤	ABBOTT POC \$5.3B
CEPHEID (MDx)	➤	DANAHER \$3.9B
ABAXIS (VET)	➤	ZOETIS \$1.8B

Global IVD market is \$75B

Market participants acquire new technology to build market presence

Nanomix mobile diagnostic system is the next healthcare technology frontier.

Management



David Ludvigson; President and CEO

Mr. Ludvigson is a financial and operating executive, and entrepreneur, with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. He has over 25 years of Life Science experience including more than 15 years in the diagnostics arena and has led numerous new product efforts. Mr. Ludvigson has concluded successful strategic transactions including acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships. Mr. Ludvigson holds both a BA and MAS from the University of Illinois.



Sherrill Lavagnino; Vice President of Engineering

Ms. Lavagnino has over 25 years of experience in developing software and integrated hardware systems. As Senior Director of Engineering at Cognex Corporation, Ms. Lavagnino was responsible for the successful launch of highly integrated manufacturing and inspection systems. Prior to Cognex Ms Lavagnino held the position of Senior Software Engineer at Isys Controls. The author of numerous patents, Sherrill graduated from Smith College.



Bradley Johnson, Ph.D.; Senior Director of Technology Development

Mr. Johnson has more than 10 years of broad experience in biotechnology and biomedical devices. His primary focus is in vitro diagnostic methods, related instrumentation and technology including microfluidics and electro chemical biosensors. He received his Ph.D. in Bioengineering from University of California, Berkeley.



John Hardsky; Chief Commercial Officer

Mr. Hardsky is an accomplished leader with over 20 years of commercialization experience in the clinical diagnostics market. John has built a strong track record of innovative concept to execution strategies that yield turnaround and growth results. While holding leadership positions in manufacturer and distribution, start-up through large companies, he launched over 20 different product platforms and value-based solutions to market. John is passionate about creating a culture of entrepreneurial spirited drive with execution confidence.

